Approximately R9 billion has been spent on the Go!Durban programme, which has incurred significant investment to date, with ...

A maiden 14-hole, 6,000m maiden diamond drill program is anticipated to commence during Q3 2025. Dan Symons, President and CEO, stated, "Khaleesi is a highly compelling, undrilled copper-gold ...

Rising Indian EMS industry driven by government support, steady demand, and potential growth, avoiding pitfalls of past tech ...

C4, e-C5 and e-Berlingo models are the first electric cars approved for the UK’s £650m ECG scheme, saving buyers up to £1,500 ...

Port Huron’s 100 Men event returns Sept. 4 with $10K in funding for local nonprofits and a sneak peek at a major waterfront development.

The first electric cars to be eligible for the government's Electric Car Grant have been announced... and they're all ...

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.